VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys
Journal of Lipid Research · 2024-02 · 65 (2) · 100497
DOI: 10.1016/j.jlr.2024.100497 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Lipid Research, 2024-02. Verfasst von Madeline M Vroom und 15 weiteren Autor:innen. Beteiligte Einrichtung: Vaxxinity, Inc, Dallas, TX, USA. Hauptthemen laut MEDLINE: Hypercholesterolemia, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Anticholesteremic Agents, Atherosclerosis. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of disease burden in the world and is highly correlated with chronic elevations of LDL-C. LDL-C-lowering drugs, such as statins or monoclonal antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9), are known to reduce the risk of cardiovascular diseases; however, statins are associated with limited efficacy and poor adherence to treatment, whereas PCSK9 inhibitors are only prescribed to a "high-risk" patient population or those who have failed other therapies. Based on the proven efficacy and safety profile of existing monoclonal antibodies, we have developed a peptide-based vaccine against PCSK9, VXX-401, as an alternative option to treat hypercholesterolemia and prevent ASCVD. VXX-401 is designed to trigger a safe humoral immune response against PCSK9, resulting in the production of endogenous antibodies and a subsequent 30-40% reduction in blood LDL-C. In this article, VXX-401 demonstrates robust immunogenicity and sustained serum LDL-C-lowering effects in nonhuman primates. In addition, antibodies induced by VXX-401 bind to human PCSK9 with high affinity and block the inhibitory effect of PCSK9 on LDL-C uptake in a hepatic cell model. A repeat-dose toxicity study conducted in nonhuman primates under good laboratory practices toxicity indicated a suitable safety and tolerability profile, with injection site reactions being the main findings. As a promising safe and effective LDL-C-lowering therapy, VXX-401 may represent a broadly accessible and convenient option to treat hypercholesterolemia and prevent ASCVD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaxxinity, Inc, Dallas, TX, USA.
- Vaxxinity, Inc, Dallas, TX, USA. Electronic address: jc@vaxxinity.com.
Zitieren
APA
Vroom, M. M., Lu, H., Lewis, M., Thibodeaux, B. A., Brooks, J. K., Longo, M. S., Ramos, M. M., Sahni, J., Wiggins, J., Boyd, J. D., Wang, S., Ding, S., Hellerstein, M., Ryan, V., Powchik, P., & Dodart, J. C. (2024). VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys. Journal of Lipid Research, 65(2), 100497. https://doi.org/10.1016/j.jlr.2024.100497
Vancouver
Vroom MM, Lu H, Lewis M, Thibodeaux BA, Brooks JK, Longo MS, et al. VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys. Journal of Lipid Research. 2024;65(2):100497. doi:10.1016/j.jlr.2024.100497
BibTeX
@article{Vroom2024,
author = {Vroom, Madeline M and Lu, Hanxin and Lewis, Maggie and Thibodeaux, Brett A and Brooks, Jeanne K and Longo, Matthew S and Ramos, Martina M and Sahni, Jaya and Wiggins, Jonathan and Boyd, Justin D and Wang, Shixia and Ding, Shuang and Hellerstein, Michael and Ryan, Valorie and Powchik, Peter and Dodart, Jean-Cosme},
title = {VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys},
journal = {Journal of Lipid Research},
year = {2024},
volume = {65},
number = {2},
pages = {100497},
doi = {10.1016/j.jlr.2024.100497}
}
EUVIMED